Oncology Today with Dr Neil Love CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Mar 23, 2026
Dr Paul G Richardson, a Dana-Farber myeloma specialist known for leading trials of novel agents, explains CELMoDs and how they more potently target cereblon to degrade Ikaros and Aiolos. He compares newer CELMoDs to older IMiDs. He reviews clinical activity, impressive combos with proteasome inhibitors and antibodies, implications for extramedullary and CNS disease, safety and near-term regulatory outlook.
AI Snips
Chapters
Transcript
Episode notes
Clinical Correlation Showing Rapid IKZF3 Loss And Response
- A patient refractory to isatuximab, pomalidomide, and dexamethasone had near-complete loss of IKZF3 after one week on mezigdomide.
- Paul G Richardson reports the marrow showed ALAS expression that disappeared and the patient achieved a complete response on the trial.
CELMoDs Work After BCMA Therapies And In Extramedullary Disease
- Mezigdomide and iberdomide show single-agent activity in heavily pretreated, BCMA-exposed myeloma with mezigdomide higher.
- Richardson cites mezigdomide ~40%+ ORR in 160+ patients and ~50% in BCMA-exposed subsets, plus activity in extramedullary disease.
Combine CELMoDs With Backbones And Bispecifics
- Combine CELMoDs with established myeloma backbones and novel immunotherapies to maximize efficacy.
- Richardson highlights high response rates when paired with PIs, CD38 antibodies, and promising combos with bispecifics and ADCs like belantamab mafodotin.